在治疗方面，以往医生们面临着诸多挑战。传统上，对于巨大膀胱平滑肌瘤，部分膀胱切除术（partial cystectomy）是常用手段。但这种手术创伤较大，患者恢复起来也比较痛苦。随着医学技术的发展，微创治疗的理念逐渐深入人心，医生们一直在探索能否用更微创的方式治疗这类疾病，既能切除肿瘤，又能减少患者的痛苦和恢复时间，这也成为了推动这项研究开展的重要动力。

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder ...

At the American Urological Association (AUA) that starts later this week, J&J is scheduled to report that TAR-200 achieved a ...

Investigators compared oncologic outcomes among patients with tumors in the bladder only vs in the bladder neck/urethra.

It involves removing both the bladder (called a cystectomy) and the prostate gland (prostatectomy) in men who have cancer that has spread to the muscles in the wall of the bladder. Often ...

who were not receiving surgery to remove the bladder (cystectomy) and nearby lymph nodes, has been discontinued after it showed no improvement over the standard chemoradiation treatment for this ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as an ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...